AustraliaASX Finishes Flat
The ASX 200 handed back early gains to finish flat, while Wall Street rose after a disappointing US jobs report. Firmus priced a $43.7 billion IPO and CSL partnered with Alentis Therapeutics.
Global Newsflix 1 min read
The ASX 200 finished flat after handing back early gains.
Wall Street rose after a disappointing US jobs report.
Firmus priced a $43.7 billion IPO and CSL partnered with Alentis Therapeutics to develop a rare kidney and liver disease drug.
Key facts
- ASX 200 finished flat
- Wall Street rose after US jobs report
- Firmus priced $43.7 billion IPO
- CSL partnered with Alentis Therapeutics
Three perspectives
Neutral
The ASX 200 result followed mixed trading. Banks, REITs and miners reversed early gains. Oil prices eased on a quiet trading day.
Positive
CSL's partnership with Alentis Therapeutics may lead to new drug developments. Wall Street's rise may indicate positive market sentiment.
Negative
The ASX 200's flat finish and reversal of early gains may indicate market uncertainty. The disappointing US jobs report may impact market confidence.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.